Amlessa® is developed by KRKA.

What development phase is Amlessa® in?

Amlessa® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Amlessa®

KRKA · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Amlessa®
Sponsor	KRKA
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Amlessa® CI brief — competitive landscape report
Amlessa® updates RSS · CI watch RSS
KRKA portfolio CI